Skip to main content
SpringerLink
Log in

The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

Recently, melatonin has been associated with cancer both in vitro and in vivo. However, the value of melatonin in the treatment of cancer remains disputable. Hence, we performed a systematic review of randomized controlled trials (RCTs) of melatonin in solid tumor cancer patients and observed its effect on tumor remission, 1-year survival, and side effects due to radiochemotherapy.

Methods

An electronic search was conducted using the databases Pubmed, Medline, EMBASE, Cochrane library, and CNKI, from inception to November 2011. Trials using melatonin as adjunct treatment concurrent with chemotherapy or radiotherapy for cancer were included. Pooled relative risk (RR) for the tumor remission, 1-year survival, and radiochemotherapy-related side effects were calculated using the software Revman 5.0.

Results

The search strategy identified 8 eligible RCTs (n = 761), all of which studied solid tumor cancers. The dosage of melatonin used in the 8 included RCTs was 20 mg orally, once a day. Melatonin significantly improved the complete and partial remission (16.5 vs. 32.6%; RR = 1.95, 95% CI, 1.49–2.54; P < 0.00001) as well as 1-year survival rate (28.4 vs. 52.2%; RR = 1.90; 95% CI, 1.28–2.83; P = 0.001), and dramatically decreased radiochemotherapy-related side effects including thrombocytopenia (19.7 vs. 2.2%; RR = 0.13; 95% CI, 0.06–0.28; P < 0.00001), neurotoxicity (15.2 vs. 2.5%; RR = 0.19; 95% CI, 0.09–0.40; P < 0.0001), and fatigue (49.1 vs. 17.2%; RR = 0.37; 95% CI, 0.28–0.48; P < 0.00001). Effects were consistent across different types of cancer. No severe adverse events were reported.

Conclusions

Melatonin as an adjuvant therapy for cancer led to substantial improvements in tumor remission, 1-year survival, and alleviation of radiochemotherapy-related side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Dakshayani KB, Subramanian P, Manivasagam T, Essa MM, Manoharan S (2005) Melatonin modulates the oxidant-antioxidant imbalance during N-nitrosodiethylamine induced hepatocarcinogenesis in rats. J Pharm Pharm Sci 8:316–321

    PubMed  CAS  Google Scholar 

  2. Xi SC, Siu SW, Fong SW, Shiu SY (2001) Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 46:52–61

    Article  PubMed  CAS  Google Scholar 

  3. Vijayalaxmi TCJ, Reiter RJ, Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575–2601

    Article  PubMed  CAS  Google Scholar 

  4. Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM (2010) Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res 12:R107

    Article  PubMed  CAS  Google Scholar 

  5. Martin-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andres O, Gonzalez P, Gonzalez-Gallego J (2008) Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 45:532–540

    Article  PubMed  CAS  Google Scholar 

  6. Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, Maestroni G (1997) Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer 5:126–129

    Article  PubMed  CAS  Google Scholar 

  7. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G (1999) Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35:1688–1692

    Article  PubMed  CAS  Google Scholar 

  8. Kim C, Kim N, Joo H, Youm JB, Park WS, Cuong DV, Park YS, Kim E, Min CK, Han J (2005) Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 46:200–210

    Article  PubMed  CAS  Google Scholar 

  9. Lissoni P (2002) Is there a role for melatonin in supportive care? Support Care Cancer 10:110–116

    Article  PubMed  CAS  Google Scholar 

  10. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G (2003) Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 35:12–15

    Article  PubMed  CAS  Google Scholar 

  11. Yan J, Shen F, Wang K, Wu M (2001) Co-antitumor effect and hepatic protection of melatonin on advanced primary liver cancer treated by transcatheter arterial chemoembolization. Acad J Sec Mil Med Univ 22:858–861

    Google Scholar 

  12. Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A, Maestroni GJ (1997) A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 23:15–19

    Article  PubMed  CAS  Google Scholar 

  13. Lissoni P (2007) Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol (Paris) 55:198–200

    Article  CAS  Google Scholar 

  14. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53:43–46

    Article  PubMed  CAS  Google Scholar 

  15. Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G, Lissoni P (2003) Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 23:1951–1954

    PubMed  CAS  Google Scholar 

  16. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E (2011) Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther [Epub ahead of print]

  17. Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Crispino S, Tancini G, Tisi E, Archili C, De Toma D, Pipino G, Et A (1992) Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 49:336–339

    Article  PubMed  CAS  Google Scholar 

  18. Lissoni P, Barni S, Ardizzoia A, Tancini G, Conti A, Maestroni G (1994) A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 73:699–701

    Article  PubMed  CAS  Google Scholar 

  19. Lissoni P, Brivio F, Fumagalli L, Messina G, Vigore L, Parolini D, Colciago M, Rovelli F (2008) Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res 28:1377–1381

    PubMed  CAS  Google Scholar 

  20. Lissoni P, Brivio O, Brivio F, Barni S, Tancini G, Crippa D, Meregalli S (1996) Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res 21:239–242

    Article  PubMed  CAS  Google Scholar 

  21. Lissoni P, Ardizzoia A, Barni S, Paolorossi F, Tancini G, Meregalli S, Esposti D, Zubelewicz B, Braczowski R (1995) A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients. Oncol Rep 2:871

    PubMed  CAS  Google Scholar 

  22. Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R, Et A (1994) A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69:196–199

    Article  PubMed  CAS  Google Scholar 

  23. Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C, Conti A, Maestroni GJ (1990) Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension. Anticancer Res 10:1759–1761

    PubMed  CAS  Google Scholar 

  24. Lissoni P, Mandala M, Brivio F (2000) Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin. Eur Urol 38:115–118

    Article  PubMed  CAS  Google Scholar 

  25. Lissoni P, Pittalis S, Ardizzoia A, Brivio F, Barni S, Tancini G, Pelizzoni F, Maestroni GJ, Zubelewicz B, Braczkowski R (1996) Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. Support Care Cancer 4:313–316

    Article  PubMed  CAS  Google Scholar 

  26. Brackowski R, Zubelewicz B, Romanowski W, Lissoni P, Barni S, Tancini G, Maestroni GJ (1994) Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin. J Biol Regul Homeost Agents 8:77–80

    PubMed  CAS  Google Scholar 

  27. Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557–1562

    Article  PubMed  CAS  Google Scholar 

  28. Cardinali DP, Esquifino AI, Srinivasan V, Pandi-Perumal SR (2008) Melatonin and the immune system in aging. Neuroimmunomodulation 15:272–278

    Article  PubMed  CAS  Google Scholar 

  29. Schernhammer ES, Razavi P, Li TY, Qureshi AA, Han J (2011) Rotating night shifts and risk of skin cancer in the nurses’ health study. J Natl Cancer Inst 103:602–606

    Article  PubMed  Google Scholar 

  30. Adriaens I, Jacquet P, Cortvrindt R, Janssen K, Smitz J (2006) Melatonin has dose-dependent effects on folliculogenesis, oocyte maturation capacity and steroidogenesis. Toxicology 228:333–343

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, The First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Road, The City of Weihui, Xinxiang, Henan Province, China

    Ye-min Wang, Yi-zhong Lu & Ting-fang Dong

  2. Department of Surgery, The First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Road, The City of Weihui, Xinxiang, Henan Province, China

    Bao-zhe Jin, Fang Ai, Chang-hong Duan & Qing-lin Fu

Authors
  1. Ye-min Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bao-zhe Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fang Ai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chang-hong Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi-zhong Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ting-fang Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qing-lin Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qing-lin Fu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Ym., Jin, Bz., Ai, F. et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 69, 1213–1220 (2012). https://doi.org/10.1007/s00280-012-1828-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-1828-8

Keywords

Search

Navigation